News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
TradingView Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Indivior Pharmaceuticals Inc. (INDV) is identified as a strong growth stock due to its favorable Zacks Growth Style Score and top Zacks Rank. The article highlights three key factors: strong projected earnings growth of 46.4%, robust year-over-year cash flow growth of 36%, and promising …
This article provides an earnings forecast for Indivior PLC (INDV), highlighting its current earnings forecast score, average price target, and analyst ratings. Based on 5 analysts, the stock has a "Buy" trend with a target price of $49.000, suggesting a 27.37% upside. The report …
Assenagon Asset Management S.A. has acquired 1,540,928 shares of Indivior PLC (NASDAQ:INDV), representing a 1.26% stake worth approximately $63.2 million. Institutional investors now collectively own 60.33% of the company. Indivior recently reported strong quarterly earnings of $5.75 per share, surpassing full-year analyst expectations, while …
This page provides news and analysis for Indivior PLC (INDV) stock. It includes current stock price, market capitalization, P/E ratio, and states that more news will be available soon. The platform, TradingKey, offers general information and does not provide financial advice.
Supernus Pharmaceuticals and Indivior Pharmaceuticals announced a Q2 2026 earnings beat and their planned all-stock merger. The combined entity will focus on central nervous system drugs, aiming for $2.2 billion in annual revenue and $125 million in annual cost savings. The merger, expected to …
HC Wainwright has increased its Q3 2026 EPS estimates for Indivior (NASDAQ:INDV) to $0.93 from $0.78, with forecasts rising through FY2030. Despite a recent price target cut by Barclays, analyst sentiment remains a "Moderate Buy" with an average target of $45.17. Indivior's shares opened …
Indivior Pharmaceuticals, Inc. (INDV) has released its Q2 2026 earnings report, detailing an increase in net revenue driven by strong U.S. sales of SUBLOCADE. The company also announced a proposed all-stock merger with Supernus Pharmaceuticals, Inc., which includes a conditional $1 billion special cash …
Indivior Pharmaceuticals, Inc. (INDV) is positioned as a key player in opioid dependence treatment, with strong analyst consensus pointing to a 36% upside potential. The company's focus on buprenorphine-based treatments, robust revenue growth of 19.20%, and a product pipeline including SUBLOCADE and SUBOXONE contribute …
Supernus Pharmaceuticals and Indivior Pharmaceutical are merging in an all-stock transaction valued at $1.8 billion, aiming to create a stronger entity in the CNS therapeutics space. The combined company, to be named Supernus, Inc., will leverage commercial and pipeline synergies across neurological and psychiatric …
Indivior plc. (INDV.L, INDV) has pre-announced positive earnings, revising its fiscal year 2026 revenue guidance upwards from an estimated range of $1.215 - $1.285 Billion to $1.295 - $1.365 Billion. This announcement is part of a broader calendar of earnings pre-announcements available through RTTNews. …
Brain drug developers Supernus and Indivior have announced a merger aimed at combining their portfolios of neurological drugs. The new entity, to be called Supernus, will have a combined revenue of $2 billion (2025 figures) and aims to achieve annual cost reductions of $125 …
Stock chart with red arrow going up ©Pixabay Indivior Pharmaceuticals Inc. (NASDAQ:INDV) reported better-than-expected second-quarter 2026 results on Monday, driven by record sales of its opioid use disorder treatment SUBLOCADE, while raising its full-year financial guidance. The stronger outlook sent the pharmaceutical company's shares …
Indivior Pharmaceuticals Inc. (NASDAQ:INDV) saw its stock rise by 9.22% after reporting strong second-quarter results that exceeded analyst expectations. The company also raised its full-year 2026 revenue and adjusted EBITDA guidance, driven by record SUBLOCADE net revenue. This performance reflects strong operational execution and …
Supernus Pharmaceuticals and Indivior Pharmaceuticals are merging in an all-stock deal to form a $2.2 billion central nervous system (CNS) biopharmaceutical company. The combined entity, operating as Supernus, Inc., will integrate Indivior's opioid use disorder franchise, centered on SUBLOCADE, with Supernus's diverse neurology and …
Indivior Pharmaceuticals reported strong second-quarter 2026 financial results, with total net revenue up 14% year-over-year to $343 million and SUBLOCADE net revenue increasing by 21% to $253 million. The company has raised its full-year 2026 guidance, now expecting total SUBLOCADE net revenue growth of …
This article announces the filing of Form 4 for Indivior PLC on August 3rd. It appears to be a very brief notification from Investing.com, typical of automated financial news updates regarding regulatory filings. The content primarily consists of navigation, advertisements, and market data rather …
Indivior PLC (NASDAQ:INDV) has received an average "Moderate Buy" recommendation from seven brokerages, with an average 12-month price target of $43.67. The company's stock opened at $40.01, and analysts project full-year earnings of $4.05 per share. Recent insider transactions show executives selling shares under …
Indivior PLC reported strong Q2 2026 financial results, with adjusted EBITDA surging 111% driven by its opioid use disorder treatment, SUBLOCADE. Despite exceeding analyst expectations, the company's stock experienced a slight decline, likely due to investor caution regarding its proposed merger with Supernus Pharmaceuticals. …
Indivior and Supernus Pharmaceuticals announced an all-stock merger of equals, expected to close in Q4 2026, creating a CNS-focused biopharmaceutical company with approximately $2.2 billion in pro forma trailing-12-month net revenue. The combined entity will retain the Supernus name and be led by Supernus …
This article from OpenSecrets details Indivior PLC's lobbying activities and lobbyists for the year 2023. It identifies 19 named lobbyists, with 15 (78.9%) having a "revolving door" background, meaning prior federal government employment. The report breaks down lobbyists by hiring firm, including Williams & …
Indivior PLC (INDV) has a current financial score of 7.94, ranking 87th out of 155 in the Pharmaceuticals industry, indicating a weak financial status despite high operating efficiency. The company reported a 19.17% year-over-year increase in quarterly revenue to $317.00 million and a 93.48% …
Indivior Ltd. has an estimated 1,015 employees worldwide as of March 2026, marking a 25.4% decline in headcount since 2023. The Pharmaceuticals company, headquartered in Bon Air, Virginia, is actively hiring with 50 job postings in 2026, though this represents a 5.8% decline from …
This article provides a valuation analysis of Indivior PLC (INDV), highlighting its strong valuation score of 9.73, which ranks it highly within the Pharmaceuticals industry. It details the company's current P/E ratio, its market capitalization, and stock performance, while noting that data for P/B, …
This article provides a comprehensive stock analysis of Indivior PLC (INDV) by TradingKey, highlighting its strong fundamentals, high growth potential, and "fairly valued" status within the Pharmaceuticals industry. The analysis details Indivior's score, key insights, and an overview of its product portfolio for substance-use …
This article provides a risk assessment for Indivior PLC (INDV), highlighting its current risk score of 6.43, ranking 53 out of 155 in the Pharmaceuticals industry. The company's beta of 1.18 suggests it tends to outperform during market uptrends but underperform during downtrends. The …
This OpenSecrets profile details Indivior PLC's lobbying activities for 2026. The company, operating in the Pharmaceuticals/Health Products industry, spent $250,000 on direct lobbying efforts between January 1 and March 31, 2026. This profile includes sections on hired firms, lobbyists, issues, agencies, and bills related …
This article provides a brief overview of Indivior PLC's (INDV) revenue breakdown, focusing on its regional contribution. As of a past report, the United States accounted for 85.03% of the company's revenue, while the Rest of World contributed 14.97%. The document indicates that detailed …
This article provides an overview of Indivior PLC's (INDV) dividend history and stock splits, noting that no dividend data is available for the past five years. It also includes current stock performance metrics such as market capitalization and P/E ratio, and basic contact information …
Indivior (INDV) currently has a short interest of 11.28 million shares, representing 9.32% of its public float, as of July 15, 2026. This indicates a 4.61% increase in short interest since the previous report, with a short interest ratio of 7.6 days to cover. …
Indivior Pharmaceuticals Inc. announced it will release its second-quarter 2026 financial results on Tuesday, August 4, 2026, at 7:00 a.m. U.S. EDT. Following the release, CEO Joe Ciaffoni and other leadership team members will host a live webcast presentation at 8:00 a.m. U.S. EDT …
Search by ticker symbol or company name and select a result to open its chart.